SCOHIA PHARMA is a specialty bioventure with great expertise in the field of lifestyle-related diseases such as cardiovascular, metabolic, and renal diseases.
-
Pipeline
2025.02.13
SCOHIA initites a Phase 1 Multiple-Dose Clinical Trial for SCO-240
-
Business
2024.03.29
Publication of a clinical phase 1 study of SCO-240: SSTR5 antagonist is a novel strategy to treat growth hormone-related disorders
-
Pipeline
2024.02.29
S-483, a Pre-clinical Program for 21-Hydroxylase Deficiency, Was Selected as a Support Program of AMED
Page Top